Compare VanEck Australian Floating Rate ETF (FLOT) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs Revvity Inc — how do they compare? VanEck Australian Floating Rate ETF trades at $50.94, while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while VanEck Australian Floating Rate ETF pays none, and Revvity Inc is trading nearer its 52-week high, VanEck Australian Floating Rate ETF nearer its low. Which is the better fit depends on your goals.
| FLOT | RVTY | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $51.09 | $117.75 |
52-Week Low | $50.72 | $82.26 |
Market Cap | — | $12.91B |
Enterprise Value | — | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLOT trades at $50.93, up 0.02% on the day, with a bearish technical signal from moving averages and oscillators neutral. Recent dividends include $0.18 paid on June 4, 2026, and $0.17 scheduled for July 7, 2026. The stock's support and resistance levels are consolidated around $51, indicating limited near-term price movement potential.
Outlook remains cautious due to bearish technical indicators and sensitivity to Federal Reserve rate decisions. Opportunities exist if rate hikes materialize, boosting yield appeal, but risks include inflation persistence and geopolitical tensions affecting Treasury yields. Investors should weigh income stability against interest rate volatility.
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
